SARS-CoV-2 BNT162b2 vaccine–induced humoral response and reactogenicity in individuals with prior COVID-19 disease
Steven G. Kelsen, … , Michael R. Ruggieri Sr., Nina T. Gentile
Steven G. Kelsen, … , Michael R. Ruggieri Sr., Nina T. Gentile
Published January 12, 2022
Citation Information: JCI Insight. 2022;7(4):e155889. https://doi.org/10.1172/jci.insight.155889.
View: Text | PDF
Clinical Medicine COVID-19

SARS-CoV-2 BNT162b2 vaccine–induced humoral response and reactogenicity in individuals with prior COVID-19 disease

Abstract

BACKGROUND Most individuals with prior COVID-19 disease manifest long-term protective immune responses against reinfection. Accordingly, we tested the hypothesis that humoral immune and reactogenicity responses to a SARS-CoV-2 mRNA vaccine differ in individuals with and without prior COVID-19 disease.METHODS Health care workers (n = 61) with (n = 30) and without (n = 31) prior COVID-19 disease received two 30 μg doses of Pfizer BNT162b2 vaccine 3 weeks apart. Serum IgG antibody against the spike receptor-binding domain; serum neutralizing activity; and vaccine reactogenicity were assessed longitudinally every 2 weeks for 56 days after the first injection.RESULTS The COVID-19 group manifested more rapid increases in spike IgG antibody and serum neutralizing activity after the first vaccine dose but showed little or no increase after the second dose compared with the infection-naive group. In fact, spike IgG was at its maximum level after the first dose in 36% of the COVID-19 group versus 0% of the infection-naive group. Peak IgG antibody levels were lower but appeared to fall more slowly in the COVID-19 group versus the infection-naive group. Finally, adverse systemic reactions, e.g., fever, headache, and malaise, were more frequent and lasted longer after both the first and second injection in the COVID-19 group than in the infection-naive group.CONCLUSION Individuals with prior COVID-19 disease demonstrate a robust, accelerated humoral immune response to the first dose but an attenuated response to the second dose of BNT162b2 vaccine compared with controls. The COVID-19 group also experienced greater reactogenicity. Humoral responses and reactogenicity to BNT162b2 differ qualitatively and quantitatively in individuals with prior COVID-19 disease compared with infection-naive individuals.FUNDING This work was supported by Temple University institutional funds.

Authors

Steven G. Kelsen, Alan S. Braverman, Mark O. Aksoy, Jacob A. Hayman, Puja S. Patel, Charu Rajput, Huaqing Zhao, Susan G. Fisher, Michael R. Ruggieri Sr., Nina T. Gentile

×

Figure 3

Serum neutralizing activity in COVID-19 and control groups.

Options: View larger image (or click on image) Download as PowerPoint
Serum neutralizing activity in COVID-19 and control groups. Pseudovirus ...
Pseudovirus uptake in HEK293 ACE2-overexpressing cells was assessed from luciferase activity, i.e., relative light units (RLU), and is shown on the y axis. Serum dilution is shown on the x axis. The 100% control value on the y axis represents maximal virus uptake occurring in the absence of serum. IC50 was calculated using sigmoidal 4-factor polynomial, nonlinear regression. Data are shown prevaccination (A) and day 14 (B) and day 42 (C) after first vaccine dose. Prevaccine, neutralizing activity in the COVID-19 group (n = 7) tended to be greater than that in the control group (n = 7) (IC50 7 × 10–3 vs. 2 × 10–2 dilution, respectively) but was not statistically significantly different (P = 0.20 by 2-way ANOVA). At day 14 after first injection, neutralizing activity increased greatly in the COVID-19 group (n = 21) but was unchanged in the control group (n = 21) (IC50 = 3.6 × 10–4 vs. 1 × 10–2 dilution, respectively; P < 0.03 by 2-way ANOVA for comparison of the 2 groups). In contrast, at day 42, neutralizing activity increased greatly in the control group (n = 21) but only slightly in the COVID-19 group (n = 21) (IC50 = 5 × 10–4 vs. 3 × 10–4 dilution, respectively) and was again not statistically significantly different (P = 0.11 for comparison of the 2 groups by 2-way ANOVA). For days 14 and 42, the same 21 individuals with prior COVID-19 disease and 21 control individuals were studied, and for both groups each data point is the mean ± SEM for 3 pools of 7 individuals each.